FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Atmastco IPO and Zenith Drugs IPO.
Atmastco IPO is a SME Book Built Issue IPO proposed to list at NSE SME while Zenith Drugs IPO is a SME Book Built Issue proposed to list at NSE SME.
Atmastco IPO | Zenith Drugs IPO | |
---|---|---|
Logo | ||
Issue Category | SME | SME |
Issue Type | IPO | IPO |
Process Type | Fixed Price Issue | Book Built Issue |
Listing At | NSE SME | NSE SME |
Lead Managers | Affinity Global Capital Market Private Limited | Gretex Corporate Services Limited |
Registrar | Cameo Corporate Services Limited | Bigshare Services Pvt Ltd |
Market Maker | Asnani Stock Broker Private Limited | Gretex Share Broking Private Limited |
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Atmastco IPO is up to ₹56.25 Cr whereas the issue size of the Zenith Drugs IPO is up to ₹40.68 Cr. The final issue price of Atmastco IPO is ₹77.00 per share and of Zenith Drugs IPO is ₹79.00 per share.
Atmastco IPO | Zenith Drugs IPO | |
---|---|---|
Face Value | ₹10 per share | ₹10 per share |
Issue Price (Lower) | ₹75.00 per share | |
Issue Price (Upper) | ₹79.00 per share | |
Issue Price (Final) | ₹77.00 per share | ₹79.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 1600 shares | 1600 shares |
Fresh Issue Size | 54,80,000 shares | 51,48,800 shares |
Fresh Issue Size (Amount) | up to ₹42.20 Cr | up to ₹40.68 Cr |
OFS Issue Size | 18,25,600 shares | |
OFS Issue Size (Amount) | up to ₹14.06 Cr | |
Issue Size Total | 73,05,600 shares | 51,48,800 shares |
Issue Size Total (Amount) | up to ₹56.25 Cr | up to ₹40.68 Cr |
Atmastco IPO opens on Feb 15, 2024, while Zenith Drugs IPO opens on Feb 19, 2024. The closing date of Atmastco IPO and Zenith Drugs IPO is Feb 20, 2024, and Feb 22, 2024, respectively.
Atmastco IPO | Zenith Drugs IPO | |
---|---|---|
Anchor Bid Date | Feb 16, 2024 | |
Issue Open | Feb 15, 2024 | Feb 19, 2024 |
Issue Close | Feb 20, 2024 | Feb 22, 2024 |
Basis Of Allotment (Tentative) | Feb 21, 2024 | Feb 23, 2024 |
Initiation of Refunds (Tentative) | Feb 22, 2024 | Feb 26, 2024 |
Credit of Share (Tentative) | Feb 22, 2024 | Feb 26, 2024 |
Listing date (Tentative) | Feb 23, 2024 | Feb 27, 2024 |
Anchor Lockin End date 1 | Mar 24, 2024 | |
Anchor Lockin End date 2 | May 23, 2024 |
Atmastco IPO P/E ratio is 11.6, as compared to Zenith Drugs IPO P/E ratio of 18.4.
Atmastco IPO | Zenith Drugs IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Atmastco Limited Financial Information (Restated Consolidated)Atmastco Limited's revenue increased by 156.43% and profit after tax (PAT) rose by 295.58% between the financial year ending with March 31, 2023 and March 31, 2022.
|
Zenith Drugs Limited Financial Information (Restated Consolidated)Zenith Drugs Limited's revenue increased by 24.85% and profit after tax (PAT) rose by 64.7% between the financial year ending with March 31, 2023 and March 31, 2022.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 97.39% | 100.00% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 68.43% | 69.98% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 11.6 | 18.4 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹190.46 Cr. | ₹135.48 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 23.15%% | 35.13%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 29.91%% | 37.29%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.48 | 1.51 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹6.64 | ₹4.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 23.15%% | 29.88%% |
In the Atmastco IPO retail investors (RII) are offered 34,69,600 shares while in Zenith Drugs IPO retail investors are offered 34,69,600 shares. Qualified institutional buyers (QIB) are offered 0 shares in Atmastco IPO and 8,59,200 shares in Zenith Drugs IPO.
Atmastco IPO | Zenith Drugs IPO | |
---|---|---|
Anchor Investor Reserveration | 12,88,000 shares | |
Market Maker Reserveration | 3,66,400 shares | 8,52,800 shares |
QIB | 0 shares | 8,59,200 shares |
NII | 34,69,600 shares | 6,44,800 shares |
RII | 34,69,600 shares | 15,04,000 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 69,39,200 shares | 30,08,000 shares |
Atmastco IPO subscribed 17.61x in total, whereas Zenith Drugs IPO subscribed 179.18x.
Atmastco IPO | Zenith Drugs IPO | |
---|---|---|
QIB (times) | 106.72x | |
NII (times) | 14.92x | 368.77x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 18.24x | 139.28x |
Employee (times) | ||
Other (times) | ||
Total (times) | 17.61x | 179.18x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|